Orphan Device Funding Authorized By Energy & Commerce: $25 Mil. Per Year
This article was originally published in The Gray Sheet
Executive Summary
The House Energy & Commerce Committee is authorizing additional funds for federal grants and contracts to develop devices and drugs for rare diseases
You may also be interested in...
“Safe Motherhood” Device Review Proposal Scheduled For July 31 Markup
The range of medical devices that would be affected by the "Safe Motherhood Act for Research and Treatment Act" (S 2328) is attracting concern from some segments of the industry
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.